Table 5.
Correlation between SII and neoadjuvant chemotherapy or postoperative chemotherapy of patients with gastric cancer
| Parameters | NCT
|
P-value | NNCT
|
P-value | ||||
|---|---|---|---|---|---|---|---|---|
| Low SII <600 | High SII ≥600 | χ2 | Low SII <600 | High SII ≥600 | χ2 | |||
| Cases (n) | 52 | 55 | 117 | 68 | ||||
| Chemotherapy regimen (before) | 0.442 | 0.802 | ||||||
| SOX | 20 | 15 | ||||||
| XELOX | 26 | 30 | ||||||
| Others | 6 | 10 | ||||||
| Preoperative chemotherapy times | 1.636 | 0.201 | ||||||
| <3 | 31 | 26 | ||||||
| ≥3 | 21 | 29 | ||||||
| Chemotherapy regimen (after) | 2.348 | 0.503 | 0.976 | 0.807* | ||||
| SOX | 19 | 13 | 2 | 1 | ||||
| XELOX | 19 | 22 | 37 | 17 | ||||
| Othersa | 8 | 12 | 54 | 34 | ||||
| No | 6 | 8 | 24 | 16 | ||||
| Postoperative chemotherapy times | 0.317 | 0.854 | 3.420 | 0.181 | ||||
| 0 | 6 | 8 | 24 | 16 | ||||
| <4 | 26 | 25 | 29 | 24 | ||||
| ≥4 | 20 | 22 | 64 | 28 | ||||
| Response | 4.512 | 0.211* | ||||||
| CR | 7 | 2 | ||||||
| PR | 35 | 37 | ||||||
| SD | 2 | 5 | ||||||
| PD | 8 | 11 | ||||||
Notes:
Fisher’s exact test.
Others include TS (paclitaxel and S-1), FOLFOX (folinic, oxaliplatin and fluorouracil), TCF (paclitaxel, cisplatin and fluorouracil), ECF (epirubicin, cisplatin and fluorouracil), TF (docetaxel and fluorouracil), DCF (docetaxel, cisplatin and fluorouracil) and other fluoropyrimidine-based adjuvant chemotherapy. SII is a novel systemic immune–inflammation index (SII=N×P/L), which is based on neutrophil (N), platelet (P) and lymphocyte (L) counts.
Abbreviations: CR, complete response; NCT, neoadjuvant chemotherapy; NNCT, non-neoadjuvant chemotherapy; PD, progression of disease; PR, partial response; SD, stable disease; SOX, S-1 and oxaliplatin; XELOX, oxaliplatin and capecitabine.